These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32814482)

  • 1. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
    Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
    Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Xing P; Wang M; Zhao J; Zhong W; Chi Y; Xu Z; Li J
    Thorac Cancer; 2021 Oct; 12(20):2825-2828. PubMed ID: 34409776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
    Liu L; Liu Y; Gong L; Zhang M; Wu W
    Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.
    Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S
    Front Immunol; 2022; 13():953229. PubMed ID: 35911723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
    Chu L; Chen Y; Liu Q; Liang F; Wang S; Liu Q; Yu H; Wu X; Zhang J; Deng J; Ai D; Zhu Z; Nie Y; Zhao K
    Oncologist; 2021 Jun; 26(6):e925-e935. PubMed ID: 33393167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
    Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
    J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
    Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
    Front Immunol; 2021; 12():727464. PubMed ID: 34899689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
    Zhou RQ; Luo J; Li LJ; Du M; Wu QC
    BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
    Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
    Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.
    Kang NN; Zheng H; Hu JX; Cui K; Si PP; Ge W
    Kaohsiung J Med Sci; 2024 Mar; 40(3):291-295. PubMed ID: 38088519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
    Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.